C. Rochlitz

Type de document

Articles (4) Colloques et conférences (2)

Co-auteur

Date

Source

Mot-clé

thérapie (6) procès (6) cancer (6) Treatment (6) Cancer (6) Therapeutics (6) Cancer (6) Breast (6) survie (5) Survival (5) Patients (5) Patients (5) toxicité (4) maladie (4) Bevacizumab (4) Toxicology (4) maladie (4) taux (3) Chemotherapy (3) Control (3) Methods (3) Ci (Chinese poetry) (3) Manufacturers' agents (3) Cycles (3) Confidence (3) Commission merchants (3) Chemotherapy (3) Doxorubicin (3) Methods (3) sécurité (2)

Documents écrit par C. Rochlitz (6) | parle de C. Rochlitz (0)

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
U. Hasler-Strub et al.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
C. Rochlitz et al. (2011)
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman et al. (2010)
hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)
K. Zaman et al. (2010)